Biological response modifiers of cancer-related neuroendocrine disorders: efficacy of the long-term dopaminergic agonist cabergoline in the treatment of breast cancer-induced hyperprolactinemia.

Lissoni, P; Vaghi, M; Pescia, S; Rovelli, F; Ardizzola, A; Valtulina, F; Malugani, F; Gardani, G; Tancini, G

Lissoni, P; Vaghi, M; Pescia, S; Rovelli, F; Ardizzola, A; Valtulina, F; Malugani, F; Gardani, G; Tancini, G.

Affiliation

Lissoni P; S Gerardo Hospital, Monza, Milano, Italy.

J Biol Regul Homeost Agents ; 18(3-4): 291-4, 2004.

Article in En | MEDLINE | ID: mdl-15786695

Subject(s)

Breast Neoplasms/complications; Dopamine Agonists/therapeutic use; Ergolines/therapeutic use; Hyperprolactinemia/drug therapy; Aged; Cabergoline; Female; Humans; Middle Aged; Prolactin/blood

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Hyperprolactinemia / Dopamine Agonists / Ergolines Type of study: Clinical_trials / Prognostic_studies Limits: Aged / Female / Humans / Middle aged Language: En Journal: J Biol Regul Homeost Agents Year: 2004 Document type: Article

Search on Google

XML

PubMed Links